Development of oncology drug response markers using transcription profiling

Current Molecular Medicine

Volumn 5, Issue 1, 2005, Pages 103-110

  Dracopoli, Nicholas C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CETUXIMAB; DIURETIC AGENT; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; PLATINUM DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; DIPLOIDY; DRUG EFFICACY; DRUG RESPONSE; EARLY DIAGNOSIS; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TRANSLOCATION; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; METASTASIS; MOLECULAR DYNAMICS; OUTCOMES RESEARCH; OVARY CANCER; PHARMACOGENOMICS; PREDICTION; PROGNOSIS; REVIEW; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 14844354489     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566524053152852     Document Type: Review

References (50)

1. Adjei, A.A. and Rowinsky, E.K. (2003) Cancer Biol. Ther. 2(4 Suppl 1), pp. S5-15.
2. Rothenberg, M.L., Carbone, D.P.and Johnson, D.H. Nat Rev Cancer, (2003) 3(4), pp. 303-9.
3. Hanahan, D. and Weinberg, R.A. (2000) Cell, 100 1), pp. 57-70.
4. Hahn, W.C. and Weinberg, R.A. (2002) Nat. Rev. Cancer, 2(5), pp. 331-41.
5. Hedenfalk, I., et al. (2001) N. Engl. J. Med., 44(8), pp. 539-48.
6. Armstrong, S.A., et al. (2002) Nat. Genet., 30 1), pp. 41-7.
7. Hussussian, C.J., et al. (1994) Nat. Genet., 8 1), pp. 15-21.
8. Zuo, L., et al. (1996) Nat. Genet., 12(1), pp. 97-9.
9. Fidler, I.J. and Kripke, M.L. (1977) Science, 197 4306), pp. 893-5.
10. Clark, E.A. et al., (2000) Nature, 406 6795), pp. 532-5.
11. Ramaswamy, S., et al. (2003) Nat. Genet., 33 1), pp. 49-54.
12. Hynes, R.O. (2003) Cell, 113(7), pp. 821-3.
13. Kang, Y., et al. (2003) Cancer Cell, 3(6), pp. 537-49.
14. van't Veer, L.J., et al. (2003) Breast Cancer Res. 5(1), pp. 57-8.
15. Ayers, M., et al. (2004) J. Clin. Oncol., 22 12), pp. 2284-93.
16. Chang, J.C., et al. (2003) Lancet, 362 9381), pp. 362-9.
17. Griffin, T.J., et al. (2002) Mol. Cell Proteomics 1(4), pp. 323-33.
18. Chen, G., et al. (2002) Mol. Cell Proteomics, 1(4), pp. 304-13.
19. Ramaswamy, S., et al. (2001) Proc. Natl. Acad. Sci. USA, 98(26), pp. 15149-54.
20. Slamon, D.J., et al. (2001) N. Engl. J. Med., 344(11), pp. 783-92.
21. Paez, J.G., et al. (2004) Science, 304 5676), pp. 1497-500.
22. Lynch, T.J., et al. (2004) N. Engl. J. Med., 350(21), pp. 2129-39.
23. Weinstein, J.N. and Pommier, C R. Y. (2003) Biol., 326(10-11), pp. 909-20.
24. Eisen, M.B., et al. (1998) Proc. Natl. Acad. Sci. USA, 95(25), pp. 14863-8.
25. Weinshilboum, R. (2003) N. Engl. J. Med., 348(6), pp. 529-37.
26. Sonneveld, P., (2000) J. Intern. Med., 247(5), pp. 521-34.
27. Petricoin, E.F., et al. (2002) Lancet, 359 9306), pp. 572-7.
28. Wulfkuhle, J.D., Liotta, L.A. and Petricoin, E.F. (2003) Nat. Rev. Cancer, 3(4), pp. 267-75.
29. Sorace, J.M. and Zhan, M. (2003) BMC Bioinformatics, 4(1), pp. 24.
30. Li, J., et al. (2002) Clin. Chem., 48(8), pp. 1296-304.
31. Qu, Y., et al. (2002) Clin. Chem., 48(10), pp. 1835-43.
32. Adam, B. L., et al. (2002) Cancer Res., 62 13), pp. 3609-14.
33. Petricoin, E. F. 3rd., et al. (2002) J. Natl. Cancer Inst., 94(20), pp. 1576-8.
34. Twine, N.C., et al. (2003) Cancer Res., 63 18), pp. 6069-75.
35. Nowell, P.C. (2002) Annu. Rev. Med., 53, pp. 1-13.
36. O'Brien, S.G., et al. (2003) N. Engl. J. Med., 348(11), pp. 994-1004.
37. Selvaggi, G., et al. (2004) Ann. Oncol., 15 1), pp. 28-32.
38. Saltz, L.B., et al. (2004) J. Clin. Oncol., 22 7), pp. 1201-8.
39. Eisenhauer, E.A., et al. (2000) J. Clin. Oncol., 18(3), pp. 684-92.
40. Gelmon, K.A., et al. (1999) J. Natl. Cancer Inst. 91(15), pp. 1281-7.
41. Rosenwald, A., et al. (2002) N. Engl J. Med., 346(25), pp. 1937-47.
42. Rosenwald, A. et al. (2003) J. Expp. Med., 198 6), pp. 851-62.
43. Lossos, I.S., et al. (2004) N. Engl. J. Med., 350(18), pp. 1828-37.
44. van de Vijver, M.J., et al. (2002) N. Eng. J. Med. 347(25), pp. 1999-2009.
45. Roberts, T.G. Jr., Lynch, T.J. Jr. and Chabner, B.A. (2003) J. Clin. Oncol., 21(19), pp. 3683-95.
46. Rowinsky, E.K. (2004) Clin. Cancer Res., 10(12 Pt 2), pp. 4220s-4226s.
47. Paik, S., et al. (2004) San Antonio. TX.
48. Cohen, M. H., et al. (2004) Clin. Cancer Res., 10(4), pp. 1212-8.
49. Herbst, R.S., et al. (2004) J. Clin. Oncol., 22(5), pp. 785-94.
50. Giaccone, G., et al. (2004) J. Clin. Oncol., 22(5), pp. 777-84.